Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Some more essential drugs to treat cancer, malaria and epilepsy have been brought under price revision and, in certain cases, price control by the Indian government. The move has not gone down well with pharmaceutical companies, reports The Pharma Letter’s India correspondent. 21 September 2016
The Russian Ministry of Health is changing the existing procedure for the launch of new drugs on the domestic market, with the aim to speed their withdrawal, according to recent statements by Veronika Skvortsova, Russia’s Minister of Health, reports The Pharma Letter’s local correspondent. 21 September 2016
Family-owned Italian pharma company Zambon has appointed Roberto Tascione as its new chief executive to drive the business on a global scale. 20 September 2016
GlaxoSmithKline’s decision to appoint Emma Walmsley as chief executive is a clear commitment to past strategy but an acknowledgement that a fresh, and arguably more commercially astute, approach is required to return the company to growth. 20 September 2016
Alnylam Pharmaceuticals has announced two key appointments to its senior leadership team, expanding the breadth of talent and experience as the company prepares for commercialization of its pipeline and global expansion. 20 September 2016
In our weekly expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, explains why we can expect mid-market companies to press on with their expansion through strategic transactions for the remainder of 2016. 20 September 2016
GlaxoSmithKline today announces that Emma Walmsley, currently chief executive of GSK’s Consumer Healthcare division, is appointed GSK CEO designate and will succeed Sir Andrew Witty as GSK CEO. 20 September 2016
British-born Christian Hogg can say with some confidence that the milestone of a Chinese company taking a drug candidate from discovery all the way to global registration will be achieved within the next two to three years. 19 September 2016
The Russian Ministry of Health is considering changing the conditions of tendering for the public procurement of high-priced drugs and vaccines, according to recent statements of an official spokesman of Veronika Skvortsova, Russia’s Minister of Health. 15 September 2016
Eli Lilly said today that Levi Garraway, a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior vice president, Global Development & Medical Affairs, for Lilly's Oncology business on January 1, 2017. 14 September 2016
In our weekly expert view piece, pharmacovigilance team leader at Berlin-based CRO, KCR, examines the increasing benefits of post-authorization studies and the collection of real-world data. 14 September 2016
Whether or not to vaccinate is one of the hottest debates in the contemporary health and pharma industry. On one hand, there is a greater amount of effective vaccines available that are able to reach a larger number of children worldwide. 14 September 2016
The discussion about anti-infective products and drug-resistant pathogens has become one of the biggest issues in health care internationally. 12 September 2016
In our quarterly special report, Dr Michelle Maxwell examines the fast-moving world of biosimilars and explores the opportunities opening up for biosimilar developers as patent exclusivity expires on numerous biologic medicines over the next ten years. 8 September 2016
US pharma giant Pfizer said today that Dr Ole Isacson, a world-renowned scientist and thought leader in neurology, will become chief scientific officer of the Neuroscience Research unit and senior vice president, effective September 16. 7 September 2016
In our weekly expert view piece, Stacie Ropka, an IP attorney, and William Rose, an associate, from Axinn Veltrop & Harkrider, examine the biosimilar approval process in the EU compared to the US. 6 September 2016